Most companies sitting on surplus cells decide to sell them long before they work out whether they can. The decision gets made in a sustainability review or a warehouse clear-out, an email goes to a broker or a buyer, and then the questions come back. What is the state of health. Can you share the datasheet. Who signs the agreement. That is where it stalls, often for weeks, sometimes for good.
The interest is real. The gap is that selling a battery is a transaction the whole organisation has to be ready for, and nobody checked whether it was.
This is the homework to do before the first email, not after it.
The clock is already running
Cells do not wait while you align internally. A pallet at 100% state of health is a different product in six months. Calendar ageing is real even in storage, demand moves between chemistries, and the buyer who wanted that volume this quarter has built their pack from someone else's stock by the next one. (What actually drives the value.)
Every week spent working out what you should have settled up front comes off the price. So settle it up front.
Who can actually say yes
In a lot of companies no single person owns the decision to sell surplus stock. It sits between procurement, the project that ordered the cells, sustainability, finance and legal, and each one assumes another is driving.
When a buyer asks a direct question and the answer needs four internal people to agree, you get silence, not an answer.
Before you go to market, name three things: who owns the decision, who has signature authority on a sales contract, and who in finance signs off on accepting a market price instead of book value. If those three are not named, you are not ready to sell. You are ready to start a conversation about selling, which is a different thing, and a buyer can feel the difference.
Whether you are allowed to sell them at all
This is the one that surprises people. Owning the cells does not always mean you are free to resell them.
Supply agreements, especially for pre-series, sample or prototype cells, can carry resale restrictions, field-of-use limits, or clauses that route end-of-life material back to the original supplier. The cells are in your warehouse and on your books, and you still might not have the right to put them on the market without the supplier signing off.
Read the contract before you offer the stock, not after a buyer is at the table.
What you can share, and who controls that
A buyer cannot commit to cells they cannot assess. They need the datasheet, the specs, photos, test data. (How buyers read a spec sheet.) That information is often gated by an NDA or IP terms with your cell supplier, not just by your own confidentiality policy.
So the question is not only whether you are comfortable sharing it. It is whether you are contractually allowed to, and if you need the supplier's permission, who asks them and how long that takes. Plenty of companies discover the answer is no, or not without a sign-off, only once a buyer has already asked. Run that review before the listing goes out.
There is a brand dimension too. Decide up front whether leadership is fine with your cells reaching the open market, and under what conditions: anonymised, vetted buyers only, no public attribution. A good broker can structure a deal so your name never travels with the cells, but only if you have decided that is what you want. (More on selling discreetly.)
Whether you have the data or just the cells
There is a gap between having cells and having a sellable batch, and the cells are the easy part.
Pull together state of health, cycle history if any, the technical datasheet, the MSDS, and the UN38.3 report. (Why documentation wins deals.) That last one matters more than people expect. Pre-series and sample cells often never had UN38.3 testing run, and without it you cannot move them by air, and many road and sea buyers will not touch them. Finding that out mid-deal kills momentum. Finding it out early gives you time to get the testing done.
If the data is scattered across PDFs, project folders and someone's inbox, gathering it is itself a week of work. Start it before a buyer is waiting on it.
Product or waste, and you decide which
Are you selling these cells as a product for second-life use, or disposing of them as waste? The answer changes the legal route entirely: which rules apply, what documentation you need, what EPR and economic-operator obligations land on you, and how the goods can cross a border. (Exporting used batteries legally.)
This is a decision, not a fact you look up, and it has to be made internally before anything moves. A batch sold as product and a batch shipped as waste are two different transactions with two different paper trails.
What you will stand behind
A buyer will ask what you warrant. Sold as-is. Who carries liability if a cell underperforms or fails after handover. With no internal position on this, the contract stage drags while you build one under pressure from a buyer who wants to close.
Decide your stance before you are negotiating it.
Do the homework once
None of this is hard. It is unglamorous, and it gets skipped because the decision to sell feels like the hard part and everything after it feels like admin.
It is not admin. It is the difference between a sale that closes in weeks and one that dies in a thread of unanswered questions. A seller who shows up knowing who signs, what they can share, how the cells are classified, and where the documents are is a seller a buyer takes seriously, and a seller who gets a better price, because none of that risk has to be priced in.
Work through the list before you reach out. If you want a hand doing it, that is most of what our desk does before a single cell is listed.
Hero image: Vanya Smythe via Unsplash, treated in Cling brand colours.